Weight-Loss Drugs Linked to Higher Osteoporosis Risk, Study Finds.

Study Links Popular Weight-Loss Medications to Bone Disorders

According to TSN.ua: A study conducted by researchers at the University of Pennsylvania has uncovered a connection between weight-loss medications—particularly GLP-1 receptor agonists—and an elevated risk of skeletal conditions such as osteoporosis and gout. These findings were published in The Washington Post and presented at the annual meeting of the American Academy of Orthopaedic Surgeons.

Key Risks Identified with GLP-1 Drugs

After analyzing data from nearly 150,000 patients, the research revealed the following increased risks:

• Osteoporosis risk rose by 30%,
• Gout risk increased by 12%,
• Osteomalacia—a serious bone tissue disorder—saw a 150% increase,
• Tendon rupture risk climbed by 50%.

These figures highlight the potential dangers associated with GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound.

Postmenopausal women are particularly vulnerable to fractures, as they may be more susceptible to the negative effects of these medications on bone health. Experts therefore advise paying close attention to possible hormonal imbalances, nutrient deficiencies, and physical stress that could compound treatment-related risks. Patients should exercise caution when using these drugs, especially those with pre-existing risk factors for skeletal diseases.

These findings could significantly impact clinical practice, making caution in prescribing GLP-1 medications a critical component of weight-loss treatment plans. Healthcare providers must assess individual patient risks and overall health before selecting a treatment approach, particularly for vulnerable populations. The study also underscores the need for further research to better understand the long-term effects of these drugs.